Literature DB >> 6432967

Pharmacokinetics of intraventricular administration.

J M Collins.   

Abstract

The widespread use of neurosurgical devices for intraventricular drug delivery has led to an escalation in the number of CSF pharmacokinetic studies. When experimental data for ventricular CSF concentration vs. time are normalized for dose and plotted for drugs with a wide range of physical properties, there is a remarkably narrow range. Simulations from a distributed model for the central nervous system suggest that the narrow range of observed CSF half-times following bolus administration is a consequence of physiologic limits upon rate of drug removal from CSF. Whereas bulk flow of CSF establishes minimum rate of drug washout, diffusion through brain tissue and subsequent removal by capillaries establishes a maximum rate of drug egress which is only seven times the minimum rate. Predictions of CSF concentration vs. time can be made based upon the capillary exchange rate for a particular drug, which could be estimated or calculated from CSF concentration measurements following systemic administration. Simulations are also presented of steady-state CSF concentrations during continuous ventricular infusions.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6432967     DOI: 10.1007/bf00165710

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  17 in total

1.  An electric analogue for uptake and exchange of inert gases and other agents.

Authors:  W W MAPLESON
Journal:  J Appl Physiol       Date:  1963-01       Impact factor: 3.531

2.  Chronic ventricular cerebrospinal fluid sampling, drug injections, and pressure monitoring using subcutaneous reservoirs in monkeys.

Authors:  J H Wood; D G Poplack; W J Flor; E N Gunby; A K Ommaya
Journal:  Neurosurgery       Date:  1977 Sep-Oct       Impact factor: 4.654

3.  Distributed model for drug delivery to CSF and brain tissue.

Authors:  J M Collins; R L Dedrick
Journal:  Am J Physiol       Date:  1983-09

4.  Misonidazole blood and cerebrospinal fluid kinetics in monkeys following intravenous and intrathecal administration.

Authors:  D Gangji; D G Poplack; J Schwade; J H Wood; J M Strong
Journal:  Eur J Cancer       Date:  1981-01       Impact factor: 9.162

5.  Distribution of methotrexate in the cerebrospinal fluid and brain after intraventricular administration.

Authors:  R G Blasberg; C S Patlak; W R Shapiro
Journal:  Cancer Treat Rep       Date:  1977-07

6.  Measurements of dog blood-brain transfer constants by ventriculocisternal perfusion.

Authors:  C S Patlak; J D Fenstermacher
Journal:  Am J Physiol       Date:  1975-10

7.  Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections.

Authors:  W R Shapiro; D F Young; B M Mehta
Journal:  N Engl J Med       Date:  1975-07-24       Impact factor: 91.245

8.  A primate model for study of methotrexate pharmacokinetics in the central nervous system.

Authors:  D G Poplack; W A Bleyer; J H Wood; M Kostolich; J L Savitch; A K Ommaya
Journal:  Cancer Res       Date:  1977-07       Impact factor: 12.701

9.  Implanted system for intraventricular drug infusion in central nervous system tumors.

Authors:  S Dakhil; W Ensminger; G Kindt; J Niederhuber; W Chandler; H Greenberg; R Wheeler
Journal:  Cancer Treat Rep       Date:  1981 May-Jun

10.  Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients.

Authors:  W R Wasserstrom; J P Glass; J B Posner
Journal:  Cancer       Date:  1982-02-15       Impact factor: 6.860

View more
  10 in total

Review 1.  Systemic chemotherapy, intrathecal chemotherapy, and symptom management in the treatment of leptomeningeal metastasis.

Authors:  Stacey L Berg; Marc C Chamberlain
Journal:  Curr Oncol Rep       Date:  2003-01       Impact factor: 5.075

Review 2.  Systematic review of efficacy, pharmacokinetics, and administration of intraventricular vancomycin in adults.

Authors:  Karen Ng; Vincent H Mabasa; Ivy Chow; Mary H H Ensom
Journal:  Neurocrit Care       Date:  2014-02       Impact factor: 3.210

3.  An immunotoxin for the treatment of T-acute lymphoblastic leukemic meningitis: studies in rhesus monkeys.

Authors:  A A Hertler; D M Schlossman; M J Borowitz; D G Poplack; A E Frankel
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

Review 4.  Leukemic and lymphomatous meningitis: incidence, prognosis and treatment.

Authors:  Marc C Chamberlain; Craig Nolan; Lauren E Abrey
Journal:  J Neurooncol       Date:  2005-10       Impact factor: 4.130

Review 5.  Pharmacokinetics following intraventricular administration of chemotherapy in patients with neoplastic meningitis.

Authors:  Gudrun Fleischhack; Ulrich Jaehde; Udo Bode
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

Review 6.  Leptomeningeal metastases: a review of evaluation and treatment.

Authors:  M C Chamberlain
Journal:  J Neurooncol       Date:  1998-05       Impact factor: 4.130

7.  Continuous intrathecal treatment with methotrexate via subcutaneous port: implication for leptomeningeal dissemination of malignant tumors.

Authors:  Nobusada Shinoura; Yusuke Tabei; Ryozi Yamada; Kuniaki Saito; Masamichi Takahashi
Journal:  J Neurooncol       Date:  2007-12-12       Impact factor: 4.130

Review 8.  Systematic Review of Efficacy, Pharmacokinetics, and Administration of Intraventricular Aminoglycosides in Adults.

Authors:  Marlys LeBras; Ivy Chow; Vincent H Mabasa; Mary H H Ensom
Journal:  Neurocrit Care       Date:  2016-12       Impact factor: 3.210

Review 9.  Addressing BBB Heterogeneity: A New Paradigm for Drug Delivery to Brain Tumors.

Authors:  Jessica I Griffith; Sneha Rathi; Wenqiu Zhang; Wenjuan Zhang; Lester R Drewes; Jann N Sarkaria; William F Elmquist
Journal:  Pharmaceutics       Date:  2020-12-11       Impact factor: 6.321

Review 10.  Emerging insights into barriers to effective brain tumor therapeutics.

Authors:  Graeme F Woodworth; Gavin P Dunn; Elizabeth A Nance; Justin Hanes; Henry Brem
Journal:  Front Oncol       Date:  2014-07-21       Impact factor: 6.244

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.